Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Survey Reveals Almost Half of UK Adults Who Travel to Malaria-risk Areas do not Think that they need Antimalarial Protection[1] Despite NHS' Recommendation[2]


News provided by

Glenmark Pharmaceuticals Ltd

12 Sep, 2017, 07:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, September 12, 2017 /PRNewswire/ --

New research[1] of over 1,000 UK adults highlights that almost half (48%) of those who travel to areas at risk of malaria may be leaving themselves exposed to this potentially fatal disease. For many, lack of knowledge about where in the world malaria is a risk and lack of time to obtain a prescription of antimalarials were cited as reason for travelling without antimalarial protection. Today marks the launch of Maloff Protect[3] (atovaquone/proguanil), the first antimalarial medication available without a prescription from a pharmacy.

Each year, four million people leave the UK to travel to areas where they are likely to be at risk of malaria.[4] In 2015, over 1,400 people returned to the UK with malaria and 6 of these cases were fatal.[5]

"Malaria is a serious tropical infection that can cause people to become very ill with high fevers, chills and other flu-like symptoms such as muscle aches. It can very quickly become life-threatening if it's not treated quickly," says Dr Ellie Cannon, a London-based GP. "Malaria can affect anyone. Travellers visiting at-risk areas should follow the NHS' ABCD approach to malaria prevention, taking steps to avoid being bitten and taking antimalarial medication as appropriate."

The survey revealed a lack of knowledge about where malaria is a risk. Malaria is present in over 90 countries worldwide, mainly across tropical and subtropical regions.[6] Nearly three quarters of people (72%) didn't know that malaria was a risk in Central America and 47% within the Indian subcontinent. Importantly, almost 1 in 3 people (32%) didn't know that malaria was a risk in Africa - the continent that is home to 90% of malaria cases and 92% of deaths from malaria.[6] According to the survey, 1 in 13 people didn't take antimalarials because they didn't have time to obtain them or they didn't know where to obtain them. This statistic rose to 1 in 5 people aged 18-34.

"I'm proof that malaria doesn't discriminate," says television presenter Charlie Webster who contracted malaria whilst cycling 3,000 miles through Brazil on her way to the Olympics in Rio in 2016. "Malaria made me critically ill and very nearly killed me. Malaria is preventable - anyone travelling to countries where they may be at risk should make sure they take the necessary precautions against this potentially life-threatening illness."

Survey results also suggest that people perceive the risk of malaria to be lower depending on the purpose of their trip. 54% of people admitted that they wouldn't take antimalarials on a business trip; 51% wouldn't take antimalarials if they were going to see friends and family; 27% of people wouldn't take antimalarials if they were backpacking and 22% of people wouldn't take them if they were going on a holiday or leisure trip.

"We're delighted to be able offer travellers easier access to effective protection against malaria," says Katja Lundell, General Manager UK at Glenmark Pharmaceuticals. "Maloff Protect provides a simple, quick and convenient way for adult travellers to get the antimalarial medication they need before they travel."

Glenmark has launched Off Somewhere - a campaign encouraging travellers to be aware of the risks of malaria on their trip and the steps they can take to #BeMozzieReady. For more information and tips on malaria prevention, follow @BeMozzieReady on Instagram.

For more information visit http://www.maloffprotect.co.uk

About the Survey[1]

This research was conducted by Opinion Matters on behalf of Glenmark Pharmaceuticals in August 2017. 1001 UK adults who had holidayed abroad in the last year completed a short online survey.

About Maloff Protect[3](atovaquone/proguanil)

Maloff Protect is an antimalarial medication that is available over the counter, direct from the pharmacy without a prescription. It helps to provide a simple, quick and convenient way for travellers to obtain effective protection. Each tablet contains two active ingredients: atovaquone (250mg) and proguanil (100mg) which work by killing the malaria parasites in the liver and the bloodstream.[7],[8]

Maloff Protect only needs to be taken 1 or 2 days before departure and for 7 days after return, plus once a day at the same time during the trip.

About Malaria 

Malaria is a life-threatening infection of the blood caused by the Plasmodium parasite[9] and transmitted by the bite of the female Anopheles mosquito.[10] It is found in more than 90 countries worldwide, usually in tropical and subtropical regions including large areas of Africa, Asia, Central and South America.[6] Nearly half of the world's population is at risk of malaria and 1,200 people die each day from the disease.[6]

The NHS recommend the ABCD approach to malaria prevention which stands for having an Awareness of the Risk, taking steps to prevent being Bitten, Chemoprophylaxis (antimalarial medication) and swift Diagnosis of symptoms if they appear.[2]

About Glenmark Pharmaceuticals Ltd. 

Glenmark Pharmaceuticals Ltd. is a leading research-driven, global, integrated pharmaceutical organisation. It is ranked among the top 75 Pharma & Biotech companies in the world in terms of revenue.[11] Glenmark has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of dermatology, oncology and respiratory disease.

With 17 state-of-the-art manufacturing facilities and a commercial presence in more than 80 countries worldwide, Glenmark is dedicated to creating a positive impact by producing new treatments for unmet medical needs.

The Active Pharmaceutical Ingredients (API) division manufactures and supplies more than 190 high quality APIs to customers worldwide. Glenmark associates with leading global generic companies by supporting partnerships through advanced process chemistry skills and innovative intellectual property.

1. Data on file. Glenmark Pharmaceuticals Europe Limited. September 2017.
2. NHS Fit for Travel: Malaria [Available at: http://www.fitfortravel.nhs.uk/home.aspx]
3. Maloff Protect Summary of product Characteristics. July 2017. Glenmark Pharmaceuticals Europe Limited.
4. Office of National Statistics. Travel Trends. [https://www.ons.gov.uk/peoplepopulationand
community/leisureandtourism/datasets/ukresidentsvisitsabroad
5. Public Health England, Malaria Imported into the UK. 2015. [https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/539502/Malaria_imported_into_the_UK_2015_report.pdf]
6. World Health Organization. Malaria Fact Sheet. April 2017. [Available http://www.who.int/mediacentre/factsheets/fs094/en/]
7. Barata et al. In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites. Antimicrob. Agents Chemother. 2016 60 (7):4333-4335
8. Hahn & Pottinger. Malaria in the Traveller: How to Manage Before Departure and Evaluate Upon Return. Med Clin North Am. 2016 100(2): 289–302
9. NHS Choices: Malaria – Antimalarials [Available at: http://www.nhs.uk/Conditions/Malaria/Pages/Introduction.aspx]
10. Centers For Disease Control and Prevention. (2016) Frequently Asked Questions. [Available at:  https://www.cdc.gov/malaria/about/faqs.html]
11. SCRIP Rankings 2017

For more information, please contact:

Yasmin Sheikh
Tonic Life Communications
yasmin.sheikh@tonic.com
+44(0)20-8747-4424

Rachel Bonny
Tonic Life Communications
rachel.bonny@tonic.com
+44(0)20-7798-9919

Date of preparation: September 2017
Job code: PP-UK-MLF-0081

Modal title

Also from this source

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation, Inc....

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Leisure & Tourism

Leisure & Tourism

Medical Pharmaceuticals

Medical Pharmaceuticals

Travel

Travel

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.